CRL: Charles River Laboratories International, Inc. Company Profile & Statistics

Charles River Laboratories International, Inc. Profile

About

Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.

Info & Links

CEO

James C. Foster

Headquarters

251 BALLARDVALE STREET
WILMINGTON, MA 01887, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

Employees

19,700

Charles River Laboratories International, Inc. Statistics

Valuation Measures

Market Capitalization²

14.09B

Enterprise Value

16.52B

Enterprise Value/EBITDA(ttm)

29.88

Price to Earnings Ratio(ttm)

29.82

Price to Sales(ttm)

3.52

Price to Book(mrq)

4.95

Price to Cash(ytd)

13.45

Profitability

Gross Margin(ttm)

32.66%

Operating Margin(ttm)

12.18%

Profit Margin(ttm)

-6.01%

Return on Equity(ttm)

15.75%

Return on Invested Capital(ttm)

-4.49%

Return on Assets(ttm)

6.51%

Income Statement

Revenue(ttm)

4.00B

Revenue Per Share(ttm)

83.77

Gross Profit(ttm)

1.31B

EBITDA(ttm)³

553.03M

Net Income Available to Common(ttm)

-238.46M

Diluted EPS(ttm)

-4.85

Share Statistics

Beta (5Y Monthly)

1.38

52-Week Change

84.98%

S&P 500 52-Week Change

19.00%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

47.74M

Dividend Yield

0.00%

Float⁴

47.12M

% Held by Insiders

1.30%

% Held by Institutions

98.91%

Balance Sheet

Total Cash(mrq)

192.03M

Total Cash Per Share(mrq)

4.02

Total Debt(mrq)

2.62B

Total Debt/Equity(mrq)

92.06%

Current Ratio(mrq)

1.35%

Quick Ratio(mrq)

1.04%

Book Value Per Share(mrq)

59.63

Cash Flow

Operating Cash Flow Per Share(ytd)

4.60

Free Cash Flow(ytd)

133.79M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

CRL

Charles River Laboratories International, Inc.